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Summary 
Primary responsibility for the induction of various  acute phase reactions has been ascribed to 
interleukin 1 (Ibl), tumor necrosis factor (TNF), or I1:6, suggesting that these cytokines may 
have many overlapping activities. Thus, it is difficult to identify the cytokine primarily responsible 
for a particular biologic effect, since I1:1 and TNF stimulate one another, and both I1:1 and 
TNF stimulate I1:6.  In this work,  the contribution of I1:6 in radioprotection, induction of 
adrenocorticotropic hormone (ACTH), and induction of hypoglycemia was assessed by blocking 
Ib6 activity. Administration of anti-I1:6 antibody to otherwise untreated mice greatly enhanced 
the incidence of radiation-induced mortality, indicating that like I1:1 and TNF, I1:6 also contributes 
to innate resistance to radiation. Anti-I1:6 antibody given to I1:l-treated or TNF-treated mice 
reduced survival from lethal irradiation, demonstrating that I1:6 is also an important mediator 
of both I1:1- and TNF-induced hemopoietic recovery. A similar I1:1/I1:6 interaction was observed 
in the case of ACTH induction. Anti-I1:6 antibody blocked the I1:l-induced increase in plasma 
ACTH, whereas recombinant I1:6 by itself did not induce such an increase. Anti-I1:6 antibody 
also mitigated TNF-induced hypoglycemia, but did not reverse I1:l-induced hypoglycemia. It 
is, therefore,  likely that TNF and I1:1 differ in their mode of induction of hypoglycemia. Our 
results suggest that an interaction of I1:6 with I1:1 and TNF is a prerequisite for protection 
from radiation lethality, and its interaction with I1:1 for induction of ACTH. 
T 
he ability to utilize cytokines clinically relies on iden- 
tifying the specific pathophysiologic functions of in- 
dividual cytokines in the host's defenses. With the availability 
of pharmacological quantities  of recombinant cytokines, 
suf~dent to be evaluated in animal modds, it was originally 
anticipated that individual cytokines could be ascribed specific 
biologic activities.  Indeed, initial studies documented that 
many inflammatory processes could be reproduced by sys- 
temic administration of rib1 or of ffNF-c~, establishing these 
two cytokines as major inflammatory mediators (1, 2). Sub- 
sequent studies, however, suggested that many of the actions 
of II:1 or TNF, induding stimulation of production of acute 
phase proteins by  hepatocytes (3,  4),  stimulation of the 
hypothalamic-pituitary-adrenal axis (5-7), or hematopoietin 
1 effects (8,  9),  can be mimicked by I1:6 (10-14). 
Because I1:1 and TNF induce I1:6 (15, 16), the possibility 
that these relatively  toxic cytokines can be replaced by the 
much less toxic IL-6 presents an obvious clinical advantage. 
To examine this possibility,  we evaluated  the contribution 
of II:6 in several I1:1- and TNF-mediated activities, by testing 
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the effect of anti-Ib6 antibody (20P3) in vivo. Our results 
show that Ib6 is an essential contributor to natural resis- 
tance to lethal irradiation, to I1:1- and TNF-induced recovery 
from lethal irradiation, to induction of ACTH  1 by I1:1, and 
to TNF-induced hypoglycemia. However, Ib6 did not in- 
duce any of the aforementioned effects when administered 
by itself to mice (15, 17, and R. Neta, unpublished results). 
Therefore, we propose that obligatory interaction of IL-1 or 
TNF with IL-6 may be a prerequisite for some of the biolog- 
ical effects of these inflammatory cytokines. 
Materials and Methods 
Mice,  CD2F1  male  and  C3H/HeN  female  mice  were  pur- 
chased from the Animal Genetics and Production Branch, National 
Cancer Institute, National Institutes of Health (Frederick,  MD). 
Mice were handled as previously described  (15). 
t Abbreviation used in this paper: ACTH, adrenocorticotropic hormone. 
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24-5008; lot Ibl 2/88; sp act 3  x  10  s U/rag) was kindly provided 
by Dr. Peter Lomedico, Hoffmann-La Roche, Inc. (Nutley, NJ). 
Recombinant murine TNF (rmTNF-oq lot 4296-17;  sp act 2  x 
10  s U/mg, as assayed on L929 cells in our laboratory) was kindly 
provided by Dr. Grace Wong, Genentech Inc. (So. San Francisco, 
CA). 
Antibodies.  Rat mAb to mouse rib6 (MP5 20F3) was prepared 
using semi-purified  Cos-7 mouse II.,6 as an immunogen, as previ- 
ously described (18). The isotype control, rat mAb to B-gahctosidase 
(GLl13) was used. A rat monoclonal IgG1, anti-ILl receptor anti- 
body (35F5) was previously described (19). Chromatographically 
purified rat IgG (Sigma Chemical Co., St. Louis,  MO) was used 
as an additional control. The antibodies and recombinant cytokines 
were diluted in pyrogen-free saline on the day of injection. Anti- 
bodies were given intraperitoneally 6-20 h before intraperitoneal 
injection of the cytokines. 
Irradiation.  Mice were randomized, placed  in plexiglass  con- 
tainers, and were given whole-body irradiation at 40 cGy/min mid- 
line tissue dose, by bilaterally  positioned 6~  elements.  The radi- 
ation field was uniform within  _+2%. The number of surviving 
mice was recorded daily for 30 d. 
Immunoenzymetric Assay for IL.6 Determinations in  the Serum. 
Serum samples obtained at 2-4 h  after cytokine injections were 
assayed for IL-6  using a two-site sandwich immunoassay as described 
(18). The threshold sensitivity of this assay was  50 pg/ml. 
Measurements of  ACTH in Plasma.  ACTH was assayed  in plasma 
from decapitated mice using an 1~I RIA kit (INCSTAR Corp., 
Stillwater,  MN) as previously described (17). The ACTH antibody 
used in this assay is derived from rabbits immunized against human 
ACTH1-24, a region identical in human and routine ACTH. The 
threshold sensitivity of this assay was  8 pg/ml. 
Glucose Determination.  Levels  of glucose in serum samples were 
measured using glucose oxidase reagent kit (KODAK Ektachem 
Clinical Chemistry Slide) as described elsewhere (20). In this assay, 
hydrogen peroxide is detected based  on its oxidant activity in a 
peroxidase-catalyzed  oxidative-coupling reaction in the presence of 
chromogen to form a dye. The intensity of the dye is measured 
at 540 nm. The Kodak Ektachem-700 Analyzer was calibrated be- 
fore each  assay. 
Statistical Analysis.  Statistical evaluation of the results was car- 
ried out  using  X  a analysis and  analysis of variance  followed by 
Fisher  protected least  significant  difference  test. 
Results 
The Role of lL.6 in Innate Radioresistance.  Previous work 
has indicated that administration of anti-IL-1R or anti-TNF 
antibody results in increased mortality of irradiated mice (21). 
To examine whether endogenously produced Ib6 contributes 
to  innate  radioresistance,  anti-Ib6  antibody  was  given  to 
normal,  untreated  mice before irradiation.  Such treatment 
greatly enhanced the incidence of mortality, from 35 to 80% 
(Fig. 1). Thus, endogenously produced IL-6 clearly contributes 
to  the  survival of mice recovering from radiation  injury. 
Comparison of  lL.1 and TNF  for Induction of  lL.6.  We have 
previously shown that pretreatment with Ibl or TNF results 
in enhanced  survival of lethaUy irradiated  mice.  Since IL-1 
and TNF are known to induce IL-6, we next sought to de- 
termine the relative contribution of IL-6 in TNF- and in Ib 
1-treated mice. We first determined the levels of Ib6 in cir- 
Figure 1.  CD2F1  mice received  0.5 ml/mouse i.p. of saline, anti-IL-6 
Ab, control GLl13 Ab, or anti-IL-1R  Ab 16 h before exposure  to 825 cGy 
of  radiation. The number at the top of  the bars indicates the total number 
of animals in four independent experiments. *Significantly  different (p < 
0.001) from saline control 
culation of IL-1- or TNF-treated mice (Table 1). Consistent 
with previous findings (15), detectable serum Ib6 levels ap- 
peared even after doses as low as  10 ng of IL-1, but micro- 
gram doses of TNF were required to induce measurable cir- 
culating  Ib6.  Consequently,  a  dose  of 600/~g/mouse  of 
anti-Ib6  antibody  neutralized  serum  II.-6 in  mice given  5 
/~g/mouse of TNF,  but  this  dose was insufficient to com- 
pletely block serum IL-6 in mice given 300 ng of II.-1 (Table 
1). Therefore, in subsequent  studies of the contribution of 
Table  1.  Effect  of Anti-IL-6 Antibody on Serum Titers of 
IL-I- or TNFqnduced IL 6 
Anti-lL-6  Control 
Cytokine treatment  Saline  antibody  antibody 
~/mt 
Saline  <50  <50  <50 
IL-1  (20  rig)  745  -  532 
IL-1  (50  ng)  1,198  <50  - 
IL-1  (100  rig)  1,383  <50  - 
IL-1  (300  ng)  3,623  82  - 
TNF  (5  /~g)  121  <50  209 
CD2FI mice were given saline injections, anti-IL-6 Ab (600/~g/mouse), 
or control Ab (GLl13, 600/~g/mouse), followed by cytokine treatment 
16 h later, and were bled at 2 and 4 h after cytokine administration. Sera 
from pools of three mice/group were assessed  for IL-6. The levels of IL-6 
are shown for 2 h after IL-1 injections and 4 h after TNF injections (since 
these were the optimal levels, with the exception, however, for anti- 
IL-6 and 300 ng of IL-1 where the results of two experiments of 4 h 
of bleeding and one experiment of 2 h of  bleeding were combined). The 
results are means of two to four experiments (individuals values varied 
within  ~- 20%). 
690  Role of ILo6 in IL-1 and TNF Activities In Vivo Figure 2.  CD2F1  mice received 600/zg anti-II~6 or control Ab (GLll3 or rat Ig) injections  16 h before  treatment with IL-1 (,4) or 5/~g TNF 
(B), and 20 h later were exposed to 950 cGy of radiation.  *Significantly  different (p < 0.01) from saline +  11:1 group, and saline +  TNF group, respectively. 
Ib6  in  induction  of protection  from  radiation  lethality, 
hypoglycemia, and ACTH release, doses of I1.1 and TNF 
were used that could be neutralized by the anti-I1.6 antibody. 
The Role of lL6 in IL-1- and TNF-enhanced Survival from 
Lethal Irradiation.  Both I1-1 and TNF promote survival from 
radiation lethality (22, 23). To assess the role of I1.6 in medi- 
ating the recuperative effects of these two cytokines, mice 
were given anti-I1.6 antibody 6-20 h before administration 
of I1.1 (100 ng) or TNF (5/~g). The results (Fig. 2, A  and 
B) indicate that anti-I1.6 antibody can completely  block both 
IL-1- and TNF-enhanced survival  from lethal irradiation. 
The Role of  lL6 in 11.,1-  and TNF-induced  Hypoglycemia.  As 
previously demonstrated, both 11.1 and TNF induce, within 
2-4 h, hypoglycemia in mice (24).  Ibl,  however, is much 
more potent than TNF in inducing hypoglycemia, since as 
little as 20 ng of I1.1 induced hypoglycemia, whereas >5/~g 
of TNF was required to induce a similar decrease in blood 
glucose levels. Anti-Ib6 antibody did not change the magni- 
tude of I1.1-induced hypoglycemia (Fig. 3 A). In contrast, 
the same dose of anti-Ib6 resulted in a significant  reversal 
of TNF-induced hypoglycemia (Fig.  3 B). 
ILI/IL6 Interaction in ACTH Induction.  Our previous work 
Figure 3.  CD2Ft mice received Ab (600/~g/mouse) 16 h before 20 ng ILl (.4) or 5/xg TNF injection (B). The results are means  _+  SEM of three 
independent  experiments,  each one with a pool of three to five mice, for TNF and individual bleedings of seven mice from two independent  experiments 
for Ibl.  *Significantly different  (p <  0.05)  from saline control group.  *Significantly different  (p <  0.05)  from saline  +  TNF. 
691  Neta et al. Figure  4.  C3H/HeN mice were given Ab (600 #g/mouse) 16 h before 
100 ng I1:1 injection. The results are means _+ SEM of three independent 
experiments, each with five mice/group assayed  individually. *Significantly 
different (p < 0.01) from saline control. "Significantly  different (1, < 0.01) 
from  II:1 treatment. 
determined that I1.-1 and II.-6 interact synergistically  to in- 
duce circulating ACTH (17). To assess the contribution of 
II.-6 in Ibl-induced ACTH release, mice were given anti- 
II.-6 antibody before receiving II.-1. As  shown in Fig.  4, 
anti-Ib6 antibody blocked the ACTH response to 1I_,1. Since 
no consistent elevation ofphsma ACTH was detected in TNF- 
treated mice, similar  experiments using anti-Ib6 antibody 
were not conducted in TNF-treated mice. 
Discussion 
The availability  of neutralizing antibody to cytokines allows 
the assessment  of the contribution of individual cytokines 
and their interaction in host defenses in vivo. For example, 
our previous studies demonstrated that administration of anti- 
IL-1R and anti-TNF antibody to normal mice caused greater 
mortality upon exposure of these mice to lethal radiation (21). 
Moreover, anti-II.-1R antibody not only blocked ILl-induced, 
but also TNF-induced protection from lethal irradiation. Con- 
versely, anti-TNF antibody also reduced II.-1-induced protec- 
tion from radiation death, suggesting that these two cytokines 
induce one another in vitro and in vivo (25-28),  and that 
their interaction is necessary for enhanced survival from le- 
thal irradiation. 
11.6 not only fails to induce 11,1 or TNF, but actually has 
been reported to suppress their production (29, 30).  Thus, 
as we have previously observed, administration of II.-6 alone 
before irradiation would not be expected to lead to enhanced 
survival and would actually reduce survival from lethal ir- 
radiation (15). Despite this, injection of anti-I1,6 antibody 
in this study results in increased mortality of irradiated, normal 
mice as well as irradiated TNF- or I1,1-treated  mice. These 
observations suggest that II.-6 participates  in both innate as 
well as II..1- and TNF-induced resistance to radiation lethality. 
The failure of IL-6 by itself to improve radiation survival in- 
dicates that the activity of I1,6 only becomes manifest in the 
course of interaction with other cytokines.  This hypothesis 
is supported by our earlier report that I1,6 given together 
with suboptimal doses of Ibl resulted in synergistically en- 
hanced survival from lethal irradiation (15). Since radiation 
itself  induces the production of endogenous II.-1 (31-33) and 
TNF (34,  35),  their presence would be expected to result 
in endogenous production of Ib6. Consequently, the inter- 
action of all three cytokines, i.e., IL-1, TNF, and IL-6, would 
contribute to innate resistance of normal mice to radiation 
lethality. 
When given individually, II.-1 and TNF induce significant 
protection  from  radiation-induced  lethality  and  induce 
hypoglycemia. One possible explanation for the observed lower 
potency of TNF in both of these biologic responses may be 
related to its much lower capacity to induce Ib6 (Table 1). 
Even 20 ng dose of II.-1 induced higher levels of II.,6 than 
5/~g of TNF. Our results indicate that 600/~g of anti-Ib6 
antibody blocked radioprotection and ACTH induction with 
100 ng I1-1, whereas the hypoglycemia induced with 20 ng 
II;1 was not significantly affected  by this antibody. In contrast, 
TNF-induced hypoglycemia can be reduced by anti-II:6 an- 
tibody. This suggests that the mechanisms of induction of 
hypoglycemia by these two cytokines differ. Alternatively, 
induction of II.-6 or distribution of antibody may vary in 
different tissues. Our previous work, showing a synergistic 
interaction of IL-1 and TNF in induction of hypoglycemia 
(24),  supports the first of these two hypotheses. 
The ability to block Ibl-induced release of ACTH with 
anti-I1,6 antibody further extends our previous findings, which 
showed that Ibl and Ib6 synergize to induce ACTH (17). 
In that study, doses of 10/~g of II.-6 induced only minimal 
changes in plasma ACTH, whereas ILl alone induced ACTH 
within 2 h (a time interval also necessary for IL-1 induction 
of IL-6) (15). The combination of Ilo-1 and II.~6 induced op- 
timal levels of ACTH within 30 min. Thus, together with 
our present results,  these observations  strongly support the 
hypothesis that the simultaneous presence of both IL-1 and 
Ib6 is necessary for release of ACTH in vivo. Our attempts 
to observe similar elevation of plasma ACTH after adminis- 
tration of 5 #g TNF to C3H/HeN mice were unsuccessful 
(Perlstein  and Neta, unpublished results).  Thus, TNF may 
not induce levels  of IL6 sufficient to induce ACTH. A previous 
report, which showed that rats given IIr  alone have elevated 
plasma ACTH (13), may be explained either by a lower re- 
quirement for this interaction in rats or, alternatively, by the 
possible  presence of sufficient endogenous levels of Ibl in 
this species. 
In conclusion, these results serve to reconcile the appar- 
ently conflicting observations by many laboratories concerning 
the relative importance of the contributions of Ibl,  TNF, 
and I1,6 to a variety of pathophysiological reactions. The in- 
terdependence and  synergistic  interactions of these  three 
cytokines are apparently mandatory for many of their bio- 
logical effects. 
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